Gennaro Pagano

Prof. Gennaro Pagano is a physician-neuroscientist and pharma medical director with over 10 years of experience in translational research and early clinical development. He holds a Doctor of Medicine, Master in Epidemiology, Doctor of Philosophy in Clinical Neuroscience, and has postdoctoral training in PET molecular imaging with a focus on genetics, preclinical, and prodromal Parkinson's disease. He has a h-index of 39 on Google Scholar, and has published over 100 peer-reviewed publications in the field of neurodegeneration (common and rare movement disorders, and dementia).

Prof. Pagano currently works as an Expert Medical Director and Group Leader at Roche Pharma Research and Early Development in Switzerland and serves as also the Chair of the Medical Directors Fellowship program in Neuroscience and Rare disease (NRD). He is also Honorary Clinical Associate Professor in Neurology and Neuroimaging at the University of Exeter Medical School, and former Chair of Parkinson's Progressive Markers Initiative (PPMI) Partner Scientific Advisory Board.

Before joining Roche, Gennaro was the Lily Safra Senior Clinical Fellow in Neurology and Research & Development Leader of the Neurodegeneration Imaging Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience at the King’s College London. In this role, he designed, implemented and led several Phase 0, 1 and Phase 2 proof-of-concept trials, and published his research on peer-reviewed International journals, such as New England Journal of Medicine, Lancet Neurology, Movement Disorders, Brain, Neurology, Annals of Neurology, European Journal of Neurology, Journal Clinical Investigation among others.

Education and career

Education

• 2019-2021: European Course Diploma in Pharmaceutical Medicine (ECPM) | University of Basel, Basel

• 2018-2020: Executive Master in Business and Administration (eMBA) | Quantic School of Business and Technology, US

• 2015-2018: Doctor of Philosophy in Clinical Neuroscience (PhD) | Institute of Psychiatry, Psychology & Neuroscience, UK

• 2010-2015: Residency in Geriatrics (first-in-class with honors) | Federico II University, Italy

• 2011-2012: Master in Epidemiology, Cochrane Systematic review and Meta-Analysis (MSc) | University of Milan, Italy

• 2003-2009: Medical School (first-in-class with honors) (MD) | Federico II University, Italy

Career

• 2020-ongoing: Expert Medical Director & Group Leader | Roche Pharma Research & Early Development, Basel, Switzerland.
  • Line management responsibility of 10+ direct reports including Medical Directors, Medical Directors Fellows, Senior Clinical Scientists, Clinical Scientists and Patient Partnership Directors.
  • Squad Lead of Parkinson’s disease Strategy.
  • Clinical and scientific leadership of clinical expert teams for the development of drugs for Parkinson’s, Alzheimer’s, Neurodevelopmental and Sleep disorders, and Rare diseases.

• 2021-ongoing: Movement Disorders Network Clinical Leader | Roche Pharma Research & Early Development, Basel, Switzerland.
  • Developing the clinical strategy for drug development in Movement Disorders (Parkinson’s, Huntington’s, and Movement. Disorders)
  • Participating in partnering activities providing feedback on in-licensing or acquisition of therapeutic solutions for Movement Disorders.

• 2021-ongoing: Honorary Clinical Associate Professor in Neurology and Neuroimaging | University of Exeter Medical School, London, UK.
  • Supervising 2+ clinical fellows or MSc/PhD students and dissemination (e.g. publications) of the results of studies completed at University of Exeter Medical School
  • Co-leading strategy for the development of novel neuroimaging biomarkers for neurodegeneration.

• 2020-2021: Chair of Parkinson's Progressive Markers Initiative (PPMI) Partner Scientific Advisory Board (PSAB) | The Michael J. Fox Foundation, New York, United States.
  • Member of the Parkinson's Progressive Markers Initiative (PPMI) Steering committee as representative of the Partner Scientific Advisor.
  • Leading PPMI Partner Scientific Advisor Board meeting and strategy for 2020/2021 representing all Industry and Partners in the consortia.

• 2020-ongoing: Chair of Medical Directors Fellowship | Roche Pharma Research & Early Development, Basel, Switzerland.
  • Reshaped the NRD Fellowship programs towards a Pharmaceutical Medicine Training for potential future Medical Directors.
  • Line management responsibility of up to 4 Medical Directors Fellows.

• 2020-2020: Senior Principal Medical Director | Roche Pharma Research & Early Development, Basel, Switzerland.
  • Line management responsibility of 6+ direct reports including Medical Directors, Medical Directors Fellows, Senior Clinical Scientists, Clinical Scientists and Patient Partnership Directors - completed PASADENA phase 2 study within timelines and involved on the extended Prasinezumab Lifecycle team towards next steps in development.
  • Clinical and scientific leadership of clinical expert teams for the development of drugs for Parkinson’s (e.g. Prasinezumab - ph2-go), Alzheimer’s, Neurodevelopmental and Sleep disorders, and Rare diseases.
  • Voting member for F. Hoffmann-La Roche Ltd in Parkinson’s disease & Movement Disorders International Consortias (e.g. Michael J. Fox Foundation for Parkinson’s disease consortia and Critical Path for Parkinson’s disease).
  • Explored long-term opportunities and threats in the area of movement disorders, in collaboration with Partnering and Global Product Strategy Competitive intelligence, evaluating options, and taking proactive steps to address them and to shape the competitive landscape.

• 2019-2022: Visiting Researcher | Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK.
  • Supervised 2+ PhDs students and dissemination (e.g. publications) of the results of studies completed at King’s College London.

• 2019-2020: Translational Medicine Leader | Roche Pharma Research & Early Development, Basel, Switzerland.
  • 'Co-lead of movement disorders strategy workstream, interfaced with each department (e.g. Discovery, Biomarkers and Translational Technologies) and global function (e.g. Therapeutic Modalities, Pharmaceutical Sciences, Late Stage, Partnering).
  • Clinical and scientific leadership in Prasinezumab (large molecule in Parkinson’s disease) and undisclosed small molecules in Alzheimer’s disease F. Hoffmann-La Roche Ltd.
  • Represented the Prasinezumab team at International Congresses (ADPD 2020, MDS 2019).
  • Multiple regulatory interactions and face-to-face meetings (e.g. EMA, EunetHA, etc).
  • Organized global ad boards for clinical development plans and biomarker strategies.
  • Main driver of clinical development plans in several Due Diligences and pre-Due Diligences.

• 2016-2019: Research & Development Leader for Neurodegeneration | UK National Parkinson Foundation Centre of Excellence for Parkinson’s & Movement Disorders.
  • Supervised 35+ clinical trials with focus on: (1) protocol development, in line with GCP regulations; (2) study set up; (3) study design; (4) regulatory and ethics submission, providing advice and assistance in the preparation of documentations for Ethics, HRA, ARSAC and for the submission and expedition of all necessary approvals for research protocols; (5) extensive experience in the recruitment of a high number of patients with a variety of neurodegenerative disorders and high retention rate into longitudinal and complex research studies.
  • Participated in defining the strategy of the Neurodegeneration Group.
  • Primary drafting, coauthoring, reviewing protocols and grants/funding applications.
  • Disseminated results to media and the press.
  • 5+ direct reports and matrix coordination of 40+ individuals among MSc, PhDs, clinical research fellows, post-doc, clinicians and young PIs from diverse academic/scientific backgrounds.

External links

Placeholder